Literature DB >> 8053055

Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.

D Rea1, C Fourcade, V Leblond, M Rowe, I Joab, L Edelman, M O Bitker, I Gandjbakhch, C Suberbielle, J P Farcet.   

Abstract

B cell lymphoproliferative disorders arising in organ transplant recipients (B cell posttransplant lymphoproliferative disorders [PTLD]) are generally associated with EBV. In previous reports, B cell PTLD were shown to express the full pattern of EBV latent genes, as in vitro-established lymphoblastoid cell lines. Although viral linear DNA was detected in 40% of lymphoproliferative disorders from immunocompromised hosts, immunophenotypic studies failed to detect late EBV replicative antigens. The aim of this study was to investigate the relationship of EBV latent gene expression in B cell PTLD to morphology, clonality, and immunophenotype, and to examine the replicative state of EBV in malignant cells. For this purpose, 9 cases of EBV-related B cell PTLD were analyzed. Immunoglobulin gene rearrangements were detected by Southern blot analysis. The presence of EBV was assessed by Southern blot and by in situ hybridization. B cell differentiation antigens, adhesion and activation molecules, and EBV latent and replicative gene expression were studied using immunohistochemistry techniques. We demonstrated that EBV-related B cell PTLD exhibited varying patterns of latent viral gene expression. Higher levels of adhesion molecules were detected in latent membrane protein 1 (LMP1) or LMP1 plus EBV nuclear antigen 2 (EBNA2)-positive tumors than in LMP1 and EBNA2-negative tumors. In contrast, there was no relationship between CD21 and CD23 expression and latent EBV phenotype. Activation of the EBV replicative cycle was highlighted by BamHI Z left frame 1 expression in 5 of 9 cases. Less frequent expression of late viral proteins suggested that the initiation of the EBV lytic cycle might not always lead to virions production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053055

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  19 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Microbiome and malignancy.

Authors:  Claudia S Plottel; Martin J Blaser
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

Review 3.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Authors:  A A Brink; D F Dukers; A J van den Brule; J J Oudejans; J M Middeldorp; C J Meijer; M Jiwa
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

6.  ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation.

Authors:  M W Hornef; G Bein; D Wilhelm; L Fricke; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

7.  Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes.

Authors:  Do Nguyen-Van; Colm Keane; Erica Han; Kimberley Jones; Jamie P Nourse; Frank Vari; Nathan Ross; Pauline Crooks; Olivier Ramuz; Michael Green; Lyn Griffith; Ralf Trappe; Andrew Grigg; Peter Mollee; Maher K Gandhi
Journal:  Am J Blood Res       Date:  2011-09-09

8.  Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders.

Authors:  J J Oudejans; M Jiwa; A J van den Brule; F A Grässer; A Horstman; W Vos; P M Kluin; P van der Valk; J M Walboomers; C J Meijer
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

9.  Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.

Authors:  D T Rowe; L Qu; J Reyes; N Jabbour; E Yunis; P Putnam; S Todo; M Green
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

Review 10.  Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

Authors:  Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.